Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED.
Clinical Program Director of Genitourinary Cancers, INOVA Dwight and Martha Schar Cancer Institute, 8505 Arlington Boulevard, Suite 100, Fairfax, VA, USA.
Jeanny B
JB
Aragon-Ching
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000077143:Docetaxel; D061345:Early Medical Intervention; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D043823:Taxoids; D000077143:Docetaxel